

Statement of Principles

concerning

BENIGN NEOPLASM OF THE EYE AND ADNEXA  
(Balance of Probabilities)

(No. 42 of 2016)

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the *Veterans’ Entitlements Act 1986*.

Dated 22 April 2016

The Common Seal of the  
Repatriation Medical Authority  
was affixed to this instrument  
at the direction of:



Professor Nicholas Saunders AO

Chairperson

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Revocation 3

5 Application 3

6 Definitions 3

7 Kind of injury, disease or death to which this Statement of Principles relates 3

8 Basis for determining the factors 4

9 Factors that must exist 4

10 Relationship to service 5

11 Factors referring to an injury or disease covered by another Statement of Principles 5

Schedule 1 - Dictionary 6

1 Definitions 6

1. Name

This is the Statement of Principles concerning *benign neoplasm of the eye and adnexa* *(Balance of Probabilities)* (No. 42 of 2016).

1. Commencement

This instrument commences on 23 May 2016.

1. Authority

This instrument is made under subsection 196B(3) of the *Veterans’ Entitlements Act 1986*.

1. Revocation

The Statement of Principles concerning benign neoplasm of the eye and adnexa No. 34 of 2008, as amended, made under subsections 196B(3) and (8) of the VEA is revoked.

1. Application

This instrument applies to a claim to which section 120B of the VEA or section 339 of the *Military Rehabilitation and Compensation Act 2004* applies.

1. Definitions

The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

1. Kind of injury, disease or death to which this Statement of Principles relates
   1. This Statement of Principles is about benign neoplasm of the eye and adnexa and death from benign neoplasm of the eye and adnexa.

Meaning of **benign neoplasm of the eye and adnexa**

* 1. For the purposes of this Statement of Principles, benign neoplasm of the eye and adnexa means:
     1. a non-malignant neoplastic proliferation of the cells of the eye classified according to site as conjunctiva, cornea, retina, choroid, ciliary body, lacrimal gland, lacrimal duct and orbit; and
     2. excludes benign neoplasms of eyelids, optic nerve, meninges and orbital bone; lipoma, haemangioma, lymphangioma, melanocytic naevi, neurofibromatosis, retinal vasoproliferative tumour and ocular surface squamous dysplasia.
  2. While benign neoplasm of the eye and adnexa attracts ICD‑10‑AM code D31, in applying this Statement of Principles the meaning of benign neoplasm of the eye and adnexa is that given in subsection (2).
  3. For subsection (3), a reference to an ICD‑10‑AM codeis a reference to the code assigned to a particular kind of injury or disease in *The International Statistical Classification of Diseases and Related Health Problems*, *Tenth Revision, Australian Modification* (ICD‑10‑AM), Ninth Edition, effective date of 1 July 2015, copyrighted by the Independent Hospital Pricing Authority, ISBN 978‑1‑76007‑020‑5.

Death from **benign neoplasm of the eye and adnexa**

* 1. For the purposes of this Statement of Principles, benign neoplasm of the eye and adnexa,in relation to a person, includes death from a terminal event or condition that was contributed to by the person’s benign neoplasm of the eye and adnexa.

Note: ***terminal event*** is defined in the Schedule 1 – Dictionary.

1. Basis for determining the factors

On the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that benign neoplasm of the eye and adnexa and death from benign neoplasm of the eye and adnexa can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.

Note: ***relevant service*** is defined in the Schedule 1 – Dictionary.

1. Factors that must exist

At least one of the following factors must exist before it can be said that, on the balance of probabilities, benign neoplasm of the eye and adnexa or death from benign neoplasm of the eye and adnexa is connected with the circumstances of a person’s relevant service:

* 1. for papilloma of the conjunctiva only, acquiring persistent infection of the epithelium of the conjunctiva with a strain from the specified list of human papilloma virus (HPV) strains before the clinical onset of benign neoplasm of the eye and adnexa;

Note: ***specified list of human papilloma virus (HPV) strains*** is defined in the Schedule 1 - Dictionary.

* 1. for schwannoma of the eye and adnexa only, having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the eye or orbit at least ten years before the clinical onset of benign neoplasm of the eye and adnexa;

Note: ***cumulative equivalent dose*** and ***schwannoma*** are defined in the Schedule 1 - Dictionary.

* 1. inability to obtain appropriate clinical management for benign neoplasm of the eye and adnexa.

1. Relationship to service
   1. The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
   2. The factor set out in subsection 9(3) applies only to material contribution to, or aggravation of, benign neoplasm of the eye and adnexa where the person’s benign neoplasm of the eye and adnexa was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
2. Factors referring to an injury or disease covered by another Statement of Principles

In this Statement of Principles:

* 1. if a factor referred to in section 9 applies in relation to a person; and
  2. that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

Schedule 1 - Dictionary

Note: See Section 6

1. Definitions
   1. In this instrument:
      1. ***benign neoplasm of the eye and adnexa***—see subsection 7(2).
      2. ***cumulative equivalent dose*** means the total dose of ionising radiation received by the particular organ or tissue. The formula used to calculate the cumulative equivalent dose allows doses from multiple types of ionising radiation to be combined, by accounting for their differing biological effect. The unit of equivalent dose is the sievert. For the purposes of this Statement of Principles, the calculation of cumulative equivalent dose excludes doses received from normal background radiation, but includes therapeutic radiation, diagnostic radiation, cosmic radiation at high altitude, radiation from occupation-related sources and radiation from nuclear explosions or accidents.
      3. ***MRCA*** means the *Military Rehabilitation and Compensation Act 2004*.
      4. ***relevant service*** means:
         1. eligible war service (other than operational service) under the VEA;
         2. defence service (other than hazardous service and British nuclear test defence service) under the VEA; or
         3. peacetime service under the MRCA.
      5. ***schwannoma*** means a benign neoplasm originating from Schwann cells of the myelin sheath of neurons of peripheral, cranial or autonomic nerves, comprising two types, neurilemomas and neurofibromas.
      6. ***specified list of human papilloma virus (HPV) strains*** means HPV type 6, 11, 16, 18, 33 or 45.
      7. ***terminal event*** means the proximate or ultimate cause of death and includes the following:
         1. pneumonia;
         2. respiratory failure;
         3. cardiac arrest;
         4. circulatory failure; or
         5. cessation of brain function.
      8. ***VEA*** means the *Veterans' Entitlements Act 1986*.